Company: MDCXW
Filing Date: 2025-12-08
Form Type: 424B3
Source: 0001062993-25-017232
Chunk: 1

Company: Medicus Pharma Ltd.
Filing Date: 2025-12-08
Form: 424B3
Chunk 1
---
 Prospectus or this prospectus supplement is truthful or complete. Any representation to the contrary is a criminal offense.

<div align='center'>The date of this prospectus supplement is December 8, 2025.

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
___________________________

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported):

MEDICUS PHARMA LTD.
(Exact name of registrant as specified in its charter)</div>

| Ontario                      | 001-42408    | 98-1778211          |
| (State or other jurisdiction | (Commission  | (IRS Employer       |
| of incorporation)            | File Number) | Identification No.) |

<div align='center'>300 Conshohocken State Road, Suite 200
(Address of principal executive offices) (ZIP Code)

Registrant’s telephone number, including area code:</div>

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

| Title of each class                                                                     |     | Trading Symbols |     | Name of each exchange on which registered |
| Common shares, no par value                                                             |     | MDCX            |     | NASDAQ Capital Market                     |
| Warrants, each exercisable for one common share at an exercise price of $4.64 per share |     | MDCXW           |     | NASDAQ Capital Market                     |

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities